Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2006)
16 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2006
Slide 1: Healthcare
HEALTHCARE
Slide 2: Consistent Growth Strategy
Consistent Growth Strategy • Innovative devices which improve care and outcomes • Increase value per patient • New patient groups • International expansion 1
Slide 3: Financial Highlights
Financial Highlights • Trading revenue US$200M +23% NZ$289M +20% • Operating profit US$72M +18% NZ$104M +16% • Operating margin 35.9% • R&D investment to 6% of revenue 2
Slide 4: Sales by Product Group
Sales by Product Group Distributed 3% Respiratory Humidification Warming & 45% Neonatal 8% OSA 44% Trading revenue 12 months to 31 March 2006 3
Slide 5: Sales by Region
Sales by Region Asia Pacific Other 19% 5% Europe North 29% America 47% Trading revenue 12 months to 31 March 2006 4
Slide 6: Expanding International Presence
Expanding International Presence 5
Slide 7: Obstructive Sleep Apnea
Obstructive Sleep Apnea 65
Slide 8: Obstructive Sleep Apnea
Obstructive Sleep Apnea • Revenue grew 34% to US$88M • Masks and flow generators grew 53% • OSA treatment market continues to expand rapidly 15-20% p.a. 7
Slide 9: Flow Generators & Masks
Flow Generators & Masks • Received US CMS reimbursement for ThermoSmart Tube • Introduced HC406 petite mask • Launched Vigor8 program 8
Slide 10: Respiratory Humidification
Respiratory Humidification 98
Slide 11: Respiratory Humidification
Respiratory Humidification • Revenue growth 14% • Increasing value per to US$90M patient • Continuing rapid • Broadlane GPO contract growth of breathing circuits, Evaqua demand 10
Slide 12: Expanding Opportunities
Expanding Opportunities Invasive Ventilation Non-invasive Ventilation O2 Therapy COPD Device Coming … Humidity Therapy Laparoscopic Insufflation 11
Slide 13: Neonatal
Neonatal • Revenue growth 24% to US$16M • Warmers, neonatal breathing systems grew strongly • Introduced range of resuscitation masks, oxygen therapy nasal cannula • Increasing proportion of recurring revenue 12
Slide 14: Capacity Expansion
Capacity Expansion 13
Slide 15: Research & Development
Research & Development • Extensive new product pipeline – Masks – Flow Generators – COPD Systems – Consumables 14
Slide 16: First Half Outlook
First Half Outlook • Underlying trading revenue growth approx 20% – US$ approx 14% growth – NZ$ approx 26% growth • Operating profit NZ$44M – NZ$45M 15
Fisher & Paykel Healthcare — Shareholder Meeting (2006) on 6ix